Paragon Therapeutics Appoints Susanna High as Chief Executive Officer [Yahoo! Finance]
Dyne Therapeutics, Inc. (DYN)
Last dyne therapeutics, inc. earnings: 11/1 04:30 pm
Check Earnings Report
US:NYSE Investor Relations:
dynegy.com/investors/presentations-events
Company Research
Source: Yahoo! Finance
Former Dyne Therapeutics executive brings deep strategic and operational experience in building and leading fast-growing innovative biotech companies WALTHAM, Mass. Nov. 21, 2024 /PRNewswire/ -- Paragon Therapeutics ("Paragon"), a biotechnology company dedicated to developing best-in-class biologics, announced today that biotech industry veteran Susanna High , MBA, has been appointed as Chief Executive Officer. In this newly created role, High will lead the team's continued efforts to propel the development of a pipeline of transformative therapies and accelerate their potential impact. "I have been impressed and inspired by the Paragon's mission, scientific excellence, and sense of urgency to advance important novel treatments to patients and I am excited to be working with such a dedicated and accomplished team to maximize the potential of Paragon's technology and rapidly progress our pipeline," said High. "Susanna brings the optimal set of expertise to further Paragon's miss
Show less
Read more
Impact Snapshot
Event Time:
DYN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DYN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DYN alerts
High impacting Dyne Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
DYN
News
- Dyne Therapeutics, Inc. (NASDAQ: DYN) was upgraded by analysts at Baird R W to a "strong-buy" rating.MarketBeat
- Dyne Therapeutics, Inc. (NASDAQ: DYN) was upgraded by analysts at Raymond James to a "strong-buy" rating.MarketBeat
- Dyne Therapeutics, Inc. (NASDAQ: DYN) is now covered by analysts at Robert W. Baird. They set an "outperform" rating and a $46.00 price target on the stock.MarketBeat
- Dyne Therapeutics, Inc. (NASDAQ: DYN) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating and a $45.00 price target on the stock.MarketBeat
- Dyne Therapeutics, Inc. (NASDAQ: DYN) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $50.00 price target on the stock.MarketBeat
DYN
Earnings
- 11/12/24 - Miss
DYN
Sec Filings
- 12/11/24 - Form 4
- 12/11/24 - Form 4
- 12/11/24 - Form 144
- DYN's page on the SEC website